Corcept Therapeutics Incorporated

Corcept Therapeutics, Inc. engages in the business of discovering and developing pharmaceutical products and medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol. The company is headquartered in Redwood City, California and currently employs 730 full-time employees. The company went IPO on 2004-04-15. The firm is engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol. The company is also conducting advanced clinical trials in patients with solid tumors, Amyotrophic Lateral Sclerosis (ALS) and liver disease. The company operates through the discovery, development and commercialization of the pharmaceutical products segment. The company sells Korlym and a generic version of Korlym in the United States using sales representatives to call on physicians caring for patients with hypercortisolism (Cushing’s syndrome). The firm's portfolio of selective cortisol modulators consists of four series totaling approximately 1,000 compounds. The company sells and distributes Lifyorli in the United States. The company is developing its proprietary, selective cortisol modulator, relacorilant, as a treatment for patients with hypercortisolism.